目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T38828 | |||
Mesdopetam (IRL790) is a dopamine D3 receptor antagonist with a Ki of 90 nM and an IC50 of 9.8 μM for the human recombinant D3 receptor. It exhibits psychomotor stabilizing properties and is utilized in the study of motor and psychiatric complications associated with Parkinson's disease. | |||
T78920 | HDAC | ||
HDAC-IN-58为HDAC抑制剂,特异性针对HDAC6,其IC50值达2.06 nM。适用于慢性疾病,如神经退行性和精神疾病的研究。 | |||
T60611 | |||
Talaglumetad (hydrochloride) 是Eglumegad 的前药,Eglumegad 是II 型代谢型谷氨酸受体(mGluR2/3)有效选择性的激动剂,用于治疗焦虑等精神疾病。 | |||
T74112 | |||
Bicuculline ((+)-Bicuculline; d-Bicuculline) 甲基氯化物是一种惊厥生物碱,是选择性GABAA 受体 (GABAA receptor) 的拮抗剂,IC50为 3 μM。Bicuculline 甲基氯化物在哺乳动物中可以诱导阵挛性强直性惊厥,还可用于阻断 Ca2+激活的钾通道。Bicuculline 甲基氯化物可用于癫痫等相关精神疾病的研究。 | |||
T74668 | |||
Zicronapine (Lu 31-130) fumarate 是抗精神病药,主要通过拮抗多巴胺D1/D2受体和5-HT2A受体发挥作用,在动物模型中显示出显著的前认知效果,展现出治疗多种神经和精神疾病的可能性。 | |||
T62202 | |||
mGluR2 modulator 1 (compound 95) 是一种有效的、具有血脑屏障通透性的 mGluR2 (代谢型谷氨酸受体-2)正向变构调节剂 (EC50: 0.03 μM)。mGluR2 modulator 1 能够用于研究精神病。 | |||
T63115 | |||
Perphenazine dihydrochloride 是一种口服具有活力的多巴胺受体 (dopamine receptor) 和组胺-1 受体 (histamine-1 receptor) 拮抗剂,作用于 D2 (Ki: 0.56 nM)、D3 (Ki: 0.43 nM)、5-HT2A (Ki: 0.6 nM)。Perphenazine dihydrochloride 也能够结合 Alpha-1A 肾上腺素受体。Perphenazine dihydrochloride 能够诱导细胞凋亡,并抑制癌细胞增殖。Perphenazine dihydrochloride 能够用于研究精神疾病、癌症、炎症。 | |||
T72034 | Others | ||
LI-2242是一种强效肌醇六磷酸激酶(IP6K)抑制剂,对 IP6K1、IP6K2、IP6K3和 IPMK 的 IC50s 分别为31 nM、42 nM、8.7 nM 和1944 nM。LI-2242通过减少增强脂质吸收、脂质稳定和脂肪生成的基因的表达,改善了肝脏脂肪变性,增强体外脂肪细胞和肝细胞的线粒体耗氧率(OCR)和胰岛素信号传导。 LI-2242可改善饮食诱导的小鼠肥胖症、高血糖症和肝脂肪变性。LI-2242可用于研究 II 型糖尿病、肥胖症、代谢并发症、静脉血栓和精神疾病。 | |||
T38131 | |||
(E)-10-Hydroxynortriptyline (E-10-OH-NT) is a metabolite of Nortriptyline . Nortriptyline is a tricyclic antidepressant and the main active metabolite of Amitriptyline, and is used to relieve the symptoms of depression[1]. [1]. Shimoda K, et al. The impact of CYP2C19 and CYP2D6 genotypes on metabolism of amitriptyline in Japanese psychiatric patients. J Clin Psychopharmacol. 2002 Aug;22(4):371-8. [2]. Shimoda K, et al. Dean L. Amitriptyline Therapy and CYP2D6 and CYP2C19 Genotype. Biotechnology Information (US); 2012-2017 Mar 23. | |||
T73677 | |||
SR 142948 dihydrochloride是一种口服活性高、选择性强的非肽类神经降压素受体(NT)拮抗剂,其在h-NTR1-CHO细胞、HT-29细胞和成年大鼠脑中IC50分别为1.19 nM、0.32 nM、3.96 nM。在HT-29细胞中,该化合物能够有效拮抗NT诱导的肌醇单磷酸盐形成,IC50为3.9 nM。此外,SR 142948 dihydrochloride在体内能够阻断NT诱导的体温下降、镇痛和转向行为,且具有良好的血脑屏障通透性,适用于精神疾病研究。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPY-00357 | HNT/NTM Protein, Human, Recombinant (His) | Human | HEK293 | ||
NTM (Neurotrimin) is a Protein Coding gene. 4 alternatively spliced human isoforms have been reported. This gene encodes a member of the IgLON (LAMP, OBCAM, Ntm) family of immunoglobulin (Ig) domain-containing glycosylphosphatidylinositol (GPI)-anchored cell adhesion molecules. IgLONs have been associated with psychiatric disorders, intelligence, body weight, heart disease, and tumors. The encoded protein may promote neurite outgrowth and adhesion via a homophilic mechanism. Neurotrimin is a member of the family of neural cell adhesion molecules. Its expression pattern suggests that Ntm promotes axonal fasciculation, guides nerve fibers to specific targets and stabilizes synapses as it accumulates coincident with synaptogenesis. Diseases associated with NTM include Connective Tissue Disease and Jacobsen Syndrome.
|
|||||
TMPY-00397 | ITIH3 Protein, Human, Recombinant (hFc) | Human | HEK293 | ||
ITIH3 (Inter-Alpha-Trypsin Inhibitor Heavy Chain 3) is a Protein Coding gene. This gene encodes the heavy chain subunit of the pre-alpha-trypsin inhibitor complex. This complex may stabilize the extracellular matrix through its ability to bind hyaluronic acid. ITIH3 is involved in the stabilization of the extracellular matrix. A polymorphism (rs2535629) of ITIH3 showed the strongest association signal with susceptibility to psychiatric disorders in Caucasian populations. Common single nucleotide polymorphisms (SNPs) in or near the inter-alpha-trypsin inhibitor heavy chain H3 (ITIH3) gene have been repeatedly associated with schizophrenia and related psychiatric disorders in genome-wide association studies.ITIH3 may be a useful biomarker for the early detection of gastric cancer. Diseases associated with ITIH3 include Schizophrenia and Major Depressive Disorder.
|
|||||
TMPK-01200 | Nogo Receptor/RTN4R Protein, Cynomolgus, Recombinant (His) | Cynomolgus | HEK293 | ||
NOGO Receptor 1 (RTN4R) regulates axonal growth, as well as axon regeneration after injury. The gene maps to the 22q11.2 schizophrenia susceptibility locus and is thus a strong functional and positional candidate gene.RTN4R may modulate the genetic risk or clinical expression of schizophrenia in a subset of patients and identify additional studies that will be necessary to clarify the role of RTN4R in psychiatric phenotypes.
|
|||||
TMPY-00198 | ITIH3 Protein, Human, Recombinant (His) | Human | HEK293 | ||
ITIH3 (Inter-Alpha-Trypsin Inhibitor Heavy Chain 3) is a Protein Coding gene. This gene encodes the heavy chain subunit of the pre-alpha-trypsin inhibitor complex. This complex may stabilize the extracellular matrix through its ability to bind hyaluronic acid. ITIH3 is involved in the stabilization of the extracellular matrix. A polymorphism (rs2535629) of ITIH3 showed the strongest association signal with susceptibility to psychiatric disorders in Caucasian populations. Common single nucleotide polymorphisms (SNPs) in or near the inter-alpha-trypsin inhibitor heavy chain H3 (ITIH3) gene have been repeatedly associated with schizophrenia and related psychiatric disorders in genome-wide association studies.ITIH3 may be a useful biomarker for the early detection of gastric cancer. Diseases associated with ITIH3 include Schizophrenia and Major Depressive Disorder.
|
|||||
TMPK-00621 | CSPG5 Protein, Human, Recombinant (His) | Human | HEK293 | ||
Chondroitin sulfate proteoglycan 5 (CSPG-5), also known as neuroglycan C, has been previously associated to differentiation since it shapes neurite growth and synapse forming. CSPG-5 expression shifts in brain areas of the default mode network of suicide victims, which may reflect an impact in the pathogenesis of psychiatric diseases or support diagnostic power.
|
|||||
TMPK-01125 | FAM19A5 Protein, Mouse, Recombinant (His) | Mouse | E. coli | ||
FAM19A5 is a secretory protein that is predominantly expressed in the brain. Although the FAM19A5 gene has been found to be associated with neurological and/or psychiatric diseases, only limited information is available on its function in the brain. FAM19A5 plays a role in nervous system development from an early stage and increases its expression in response to pathological conditions in subsets of neurons and OPCs of the brain.
|
|||||
TMPK-00699 | FAM19A5 Protein, Human, Recombinant (His) | Human | E. coli | ||
FAM19A5 is a secretory protein that is predominantly expressed in the brain. Although the FAM19A5 gene has been found to be associated with neurological and/or psychiatric diseases, only limited information is available on its function in the brain. FAM19A5 plays a role in nervous system development from an early stage and increases its expression in response to pathological conditions in subsets of neurons and OPCs of the brain.
|
|||||
TMPY-00355 | HNT/NTM Protein, Human, Recombinant (hFc) | Human | HEK293 | ||
NTM (Neurotrimin) is a Protein Coding gene. 4 alternatively spliced human isoforms have been reported. This gene encodes a member of the IgLON (LAMP, OBCAM, Ntm) family of immunoglobulin (Ig) domain-containing glycosylphosphatidylinositol (GPI)-anchored cell adhesion molecules. IgLONs have been associated with psychiatric disorders, intelligence, body weight, heart disease, and tumors. The encoded protein may promote neurite outgrowth and adhesion via a homophilic mechanism. Neurotrimin is a member of the family of neural cell adhesion molecules. Its expression pattern suggests that Ntm promotes axonal fasciculation, guides nerve fibers to specific targets and stabilizes synapses as it accumulates coincident with synaptogenesis. Diseases associated with NTM include Connective Tissue Disease and Jacobsen Syndrome.
|
|||||
TMPY-03991 | DBI Protein, Human, Recombinant (His) | Human | E. coli | ||
The diazepam binding inhibitor (DBI), alternatively known as the acyl-CoA binding protein (ACBP), is involved in multiple biological actions. The polypeptide binds to the peripheral, or mitochondrial, benzodiazepine receptor and facilitates transport of cholesterol to the inner membrane to stimulate steroid synthesis. Through this action, DBI indirectly modulates gamma-aminobutyric acid (GABA)-mediated inhibitory neurotransmission. DBI can be postulated as a candidate gene for psychiatric phenotypes including anxiety, mood, and psychotic disorders. Diazepam Binding Inhibitor (DBI), also called acyl-CoA binding protein (ACBP), is a ubiquitously expressed protein originally identified based on its ability to displace diazepam from its binding site on the GABAA receptor. The mutant allele of the DBI was one of the risk factors for alcohol dependence as for the rs2276596 polymorphism.
|
|||||
TMPY-04033 | FGF-14 Protein, Canine, Recombinant | Canine | E. coli | ||
FGF14 is a member of the fibroblast growth factor (FGF) family. Members of this family possess broad mitogenic and cell survival activities, and are involved in a variety of biological processes, including embryonic development, cell growth, morphogenesis, tissue repair, tumor growth and invasion. FGF14 is probably involved in nervous system development and function. Defects in FGF14 are the cause of spinocerebellar ataxia type 27 (SCA27). It is a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCA27 is an autosomal dominant cerebellar ataxia. It is a slowly progressive disorder, with onset in late-childhood to early adulthood, characterized by ataxia with tremor, orofacial dyskinesia, psychiatric symptoms and cognitive deficits.
|
|||||
TMPY-01618 | GLO1 Protein, Mouse, Recombinant (His) | Mouse | E. coli | ||
Lactoylglutathione lyase, also known as Methylglyoxalase, Aldoketomutase, Glyoxalase I, Ketone-aldehyde mutase, S-D-lactoylglutathione methylglyoxal lyase and GLO1, is a member of the glyoxalase I family. GLO1 / Glyoxalase I is a ubiquitous cellular defense enzyme involved in the detoxification of methylglyoxal, a cytotoxic byproduct of glycolysis. Accumulative evidence suggests an important role of GLO1 expression in protection against methylglyoxal-dependent protein adduction and cellular damage associated with diabetes, cancer, and chronological aging. GLO1 / Glyoxalase I has been implicated in anxiety-like behavior in mice and in multiple psychiatric diseases in humans. GLO1 / Glyoxalase I catalyzes the conversion of hemimercaptal, formed from methylglyoxal and glutathione, to S-lactoylglutathione. GLO1 / Glyoxalase I exists in three separable isoforms which originate from two alleles in the genome. These correspond to two homodimers and one heterodimer composed of two subunits showing different electrophoretic properties. GLO1 upregulation may play a functional role in glycolytic adaptations of cancer cells.
|
|||||
TMPY-02804 | FGF-14 Protein, Human, Recombinant (isoform 1B) | Human | E. coli | ||
FGF14 is a member of the fibroblast growth factor (FGF) family. Members of this family possess broad mitogenic and cell survival activities, and are involved in a variety of biological processes, including embryonic development, cell growth, morphogenesis, tissue repair, tumor growth and invasion. FGF14 is probably involved in nervous system development and function. Defects in FGF14 are the cause of spinocerebellar ataxia type 27 (SCA27). It is a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCA27 is an autosomal dominant cerebellar ataxia. It is a slowly progressive disorder, with onset in late-childhood to early adulthood, characterized by ataxia with tremor, orofacial dyskinesia, psychiatric symptoms and cognitive deficits.
|
|||||
TMPY-01215 | NAALADL1 Protein, Human, Recombinant (His) | Human | HEK293 | ||
N-acetylated-alpha-linked acidic dipeptidase-like protein, also known as NAALADL1, NAALADase L, and Ileal dipeptidyl-peptidase, is a Single-pass type II membrane protein and a member of the peptidase M28 family and M28B subfamily. NAALADase L is mainly expressed in the distal small intestine. It is also expressed in the spleen and testis and Weakly expressed in the brain, locating mainly to the brain stem, amygdala, thalamus, and ventral striatum. NAALADase L is a chloride-activated, membrane-bound, metallopeptidase that cleaves the endogenous neuropeptide N-acetyl-aspartyl-glutamate (NAAG). NAAG acts as a partial NMDA agonist as well as a full agonist at the presynaptic metabotropic glutamate receptor 3 (mGluR3), where it acts to reduce glutamate release. NAALADase L also exhibits a dipeptidyl-peptidase IV type activity. NAALADase inhibition may be a novel therapeutic approach to reduce or inhibit heightened aggressiveness, and possibly to treat aggressive behavior associated with psychiatric disorders.
|
|||||
TMPY-02668 | NAALADL1 Protein, Mouse, Recombinant (His) | Mouse | HEK293 | ||
N-acetylated-alpha-linked acidic dipeptidase-like protein, also known as NAALADL1, NAALADase L, and Ileal dipeptidyl-peptidase, is a Single-pass type II membrane protein and a member of the peptidase M28 family and M28B subfamily. NAALADase L is mainly expressed in the distal small intestine. It is also expressed in the spleen and testis and Weakly expressed in the brain, locating mainly to the brain stem, amygdala, thalamus, and ventral striatum. NAALADase L is a chloride-activated, membrane-bound, metallopeptidase that cleaves the endogenous neuropeptide N-acetyl-aspartyl-glutamate (NAAG). NAAG acts as a partial NMDA agonist as well as a full agonist at the presynaptic metabotropic glutamate receptor 3 (mGluR3), where it acts to reduce glutamate release. NAALADase L also exhibits a dipeptidyl-peptidase IV type activity. NAALADase inhibition may be a novel therapeutic approach to reduce or inhibit heightened aggressiveness, and possibly to treat aggressive behavior associated with psychiatric disorders.
|